Hansa Biopharma: Supportive top-line clinical results in sequential gene therapy combination - Redeye

The combination of ELEVIDYS from Sarepta and Imlifidase records early supportive top-line data for patients resistant to ELEVIDYS when treating three Duchenne muscular dystrophy (DMD) patients.

Länk till analysen i sin helhet: https://www.redeye.se/research/1121292/hansa-biopharma-supportive-top-line-clinical-results-in-sequential-gene-therapy-combination?utm_source=finwire&utm_medium=RSS